Prosthetic thrombosis: echocardiography our great ally
DOI:
https://doi.org/10.37615/retic.v3n3a11Keywords:
heart valve prosthesis implantation, thrombosis, fibrinolysis.Abstract
Valve prostheses are the final treatment for many advanced valvular diseases. However, they are not exempt from
complications. For example, infective endocarditis, obstruction of the prosthetic valve (thrombosis and pannus), embolic events and periprosthetic regurgitation. Prosthetic valve thrombosis should be suspected in any patient with dyspnea or embolic phenomenon of recent onset. An appropriate diagnosis is essential in order to choose the best therapeutic strategy. This implies from the intensification of anticoagulation to more aggressive measures such as emergency surgery, fibrinolysis and even palliative measures. Our aim is to highlight the role of echocardiography in each phase of the management of this complication
Downloads
Metrics
References
Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart 2007; 93: 137-142. doi: https://doi.org/10.1136/hrt.2005.071183
Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22 (9): 975-1014. doi: https://doi.org/10.1016/j.echo.2009.07.013
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2438-2488. doi: https://doi.org/10.1161/CIR.0000000000000503
Mutuberría-Urdaniz M, Rodríguez-Palomares JF, Ferreira I, et al. Non-obstructive prosthetic heart valve thrombosis (NOPVT). Really a benign entity? Int J Cardiol 2015; 197: 16-22. doi: https://doi.org/10.1016/j.ijcard.2015.06.021
Karthikeyan G, Senguttuvan NB, Joseph J, et al. Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. Eur Heart J 2013; 34: 1557-1566. doi: https://doi.org/10.1093/eurheartj/ehs486
Castilho FM, De Sousa MR, Mendonça AL, et al. Thrombolytic therapy or surgery for valve prosthesis thrombosis: systematic review and meta-analysis. J Thromb Haemost 2014; 12: 1218-1228. doi: https://doi.org/10.1111/jth.12577
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Joffrey Eduardo Luján Valencia, Carmen Riaza Ocio, Fausto Librada Escribano, Lucía Alvarez Lacruz, Pedro María Azcárate Agüero
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
RETIC is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license https://creativecommons.org/licenses/by-nc-nd/4.0 which allows sharing, copying and redistribution of the material in any medium or format, under the following terms:
- Attribution: you must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests that the licensor endorses you or your use.
- Non-commercial: you may not use the material for commercial purposes.
- No Derivatives: if you remix, transform or build upon the material, you may not distribute the modified material.
- No Additional Restrictions: you may not apply legal terms or technological measures that legally restrict others from doing anything permitted by the license.
